HR Execs on the Move

Optinose

www.optinose.com

 
We are a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat (ENT) and allergy specialists. Our first commercial product, XHANCE® (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing our proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and, if approved, chronic rhinosinusitis without nasal polyps (also known as chronic sinusitis). In September 2017, the U.S. Food and Drug Administration (FDA) approved XHANCE for the treatment of nasal polyps in patients 18 years of age or ...
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.optinose.com
  • 1020 Stony Hill Road Suite 300
    Yardley, PA USA 19067
  • Phone: 267.364.3500

Executives

Name Title Contact Details
Krick Neely
Chief Finance Officer Profile
Keith Goldan
Chief Financial Officer Profile
Anthony Krick
Vice President and Chief Accounting Officer Profile
Michele Janis
Vice President of Finance and Acting Chief Financial Officer Profile

Similar Companies

Erfa Canada Inc

Erfa Canada Inc is a Westmount, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

PDi-Pharmaceuticals

PDi-Pharmaceuticals is a Aurora, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Erytech

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics to treat severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH`s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival. The Company`s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cell`s altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of triple-negative breast cancer. ERYTECH is based in Lyon, France and Cambridge, MA, USA, and has manufacturing sites in Lyon, France, and Princeton, New Jersey, USA.

CARGO Therapeutics

CARGO Therapeutics is a biotechnology company that is developing and delivering CAR T cell therapies to cure more cancer patients. Their cell therapies focus on addressing the primary mechanisms of failure, or resistance and relapse, to the currently a...

Vical

Vical Incorporated is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.